The renin-angiotensin-aldosterone system, or RAAS, is a peptidergic cascade with angiotensin II as its key effector. In healthy physiology it regulates blood pressure and fluid balance. In heart failure, reduced cardiac output, arterial underfilling and direct renal sympathetic stimulation push the system into overdrive, and the consequences are destructive: vasoconstriction, oxidative stress, inflammation, fibrosis of the heart and vasculature, and amplification of sympathetic nervous activity. Blocking this cascade with ACE inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors and mineralocorticoid receptor antagonists is a cornerstone of modern heart failure therapy. Yet guidelines do not routinely recommend these drugs after heart transplantation, and the question of whether the hormonal storm actually resolves once hemodynamics are corrected has remained largely unanswered.

To find out, the Vienna team enrolled patients with end-stage heart failure who were undergoing either heart transplantation or implantation of a left ventricular assist device, or LVAD, into a prospective registry. In total, 49 transplant recipients and 12 LVAD recipients were followed, with blood sampling shortly before and approximately six months after the intervention. The investigators measured NT-proBNP, the widely used marker of cardiac stress, plasma active renin concentration, aldosterone, and crucially the complete profile of circulating angiotensin peptides. Blood was drawn into tubes containing an inhibitor cocktail that instantly freezes angiotensin metabolism, allowing the researchers to capture a faithful snapshot, or fingerprint, of the circulating RAS at the moment of sampling.

The fingerprinting technique itself is a technical tour de force. Plasma samples were spiked with stable isotope-labeled internal standards for ten different angiotensin metabolites, then analyzed by liquid chromatography tandem mass spectrometry after solid-phase extraction. Because renin-dependent generation of angiotensin I is the rate-limiting step of the cascade, and ACE converts angiotensin I into angiotensin II, the relative abundance of downstream peptides such as angiotensin 1-7, angiotensin 1-5, angiotensin III and angiotensin IV reveals both the magnitude of systemic RAS activation and the mode of any pharmacological blockade. The sum of angiotensin I and angiotensin II served as a measure of the angiotensin burden carried by the classical RAS axis.

The results were unambiguous. After heart transplantation, the use of RAS inhibitors dropped significantly, as beta-blocker use fell from 63 to 2 percent and mineralocorticoid antagonist use collapsed from 55 to 8 percent, reflecting the standard de-escalation of heart failure drugs after transplant. In LVAD patients, by contrast, neurohormonal therapy remained broadly comparable before and after implantation, consistent with the strategy of continuing medication to promote reverse remodeling and myocardial recovery. Both interventions produced marked improvements in the visible signs of neurohumoral dysregulation. NT-proBNP fell from a median of 3015 to 1140 pg/mL after transplantation and from 8980 to 1836 pg/mL after LVAD implantation, while active renin concentration declined from 278 to 87 µIU/mL and from 847 to 131 µIU/mL respectively.

But the improvement stopped well short of normal. Not a single patient achieved normal NT-proBNP values after either intervention, and only 24 percent of transplant recipients and 33 percent of LVAD recipients reached normal renin levels. Plasma renin remained elevated in 76 percent of heart transplant patients and 67 percent of LVAD recipients, and in those patients clearly measurable angiotensin II persisted in the circulation. The angiotensin burden of the classical axis fell substantially after transplantation, from a median of 159 to 47 ng/L, and dropped numerically in the LVAD group from 214 to 42 ng/L, but it did not vanish. Aldosterone concentrations, notably, showed no significant change after either procedure. A tight correlation between renin and the combined angiotensin I plus angiotensin II levels, with a Spearman coefficient of 0.87, confirmed that renin remains the rate-limiting driver of the circulating cascade even after hemodynamic rescue.

Why does the hormonal system refuse to reset? The authors suggest a combination of mechanisms. In transplant recipients, persistent natriuretic peptide elevation has been attributed to cardiac denervation, immunosuppressive therapy, ventriculo-vascular uncoupling, endothelial dysfunction and subclinical allograft rejection. Prior studies have shown that natriuretic peptide levels peak within months of transplantation and decline gradually, but rarely normalize even years later; importantly, a late rise in NT-proBNP correlates strongly with allograft rejection, making these biomarkers clinically meaningful rather than mere curiosities. In LVAD patients, the picture is complicated by the devices themselves. Continuous-flow pumps may fail to stimulate arterial baroreceptors the way pulsatile flow does, potentially desensitizing receptors and raising intrinsic sympathetic tone, which in turn drives RAAS activation. Non-pulsatile kidney perfusion may independently activate the system, and preclinical work has linked continuous flow to impaired endothelial function, renal cortical artery hypertrophy and inflammatory infiltration.

The clinical implications are considerable. Ongoing angiotensin II spill-over is not a benign biochemical footnote: the peptide promotes the very processes, remodeling, fibrosis, inflammation and vascular dysfunction, that produce complications such as right ventricular failure in LVAD patients and possibly graft injury in transplant recipients. The study’s findings support a rationale for cardioprotective treatment, particularly with RAS inhibitors, in most patients after both transplantation and LVAD implantation, even though current transplant guidelines do not routinely recommend these agents. The Vienna group cautions, however, that this remains a hypothesis in this population. The impact of RAS inhibition specifically after transplantation and mechanical support should be tested in dedicated studies, and the long-term consequences of such a strategy, including interactions with immunosuppression and renal function, need careful evaluation.

Beyond its immediate therapeutic message, the study offers a conceptual shift. It reframes advanced heart failure not simply as a pumping problem that surgery can fix, but as a systemic neurohormonal disease whose imprint survives the replacement of the organ that caused it. The angiotensin fingerprints captured by mass spectrometry provide a new window into individual RAS regulation, showing exactly how pharmacological blockade reshapes the peptide landscape and where activation persists. For the growing population of patients living with transplanted hearts or mechanical circulatory support, the message is that the endocrine apparatus retains a memory of the failure it once served, and that memory may be a modifiable target for improving long-term outcomes.

Subject of Research: Persistent renin-angiotensin system activation and neurohormonal memory after heart transplantation or LVAD implantation in end-stage heart failure patients

Article Title: Memory of the renin-angiotensin system following heart transplantation or implantation of a left ventricular assist device

Article References: Memory of the renin-angiotensin system following heart transplantation or implantation of a left ventricular assist device. (n.d.). https://doi.org/10.1007/s00392-026-03018-x

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03018-x

Keywords: heart failure, heart transplantation, LVAD, renin-angiotensin system, angiotensin II, NT-proBNP, neurohormonal activation, mass spectrometry, cardiac remodeling, RAS inhibitors, aldosterone, plasma renin

The report centers on a man in his fifties who developed pump thrombosis just fourteen days after receiving a HeartMate 3 implant. The HeartMate 3, manufactured by Abbott, is a fully magnetically levitated centrifugal-flow pump designed to minimize blood trauma. Its artificial pulse feature and wide blood-flow gaps were engineered specifically to reduce the risk of thrombosis, and large randomized trials have indeed shown remarkably low rates of pump thrombosis compared with older axial-flow devices. That very success, however, means that when thrombosis does occur, clinicians may have little experience recognizing it, particularly in the early postoperative period when it is rarest and hardest to diagnose.

In this case, the patient’s initial presentation was strikingly subtle. He remained clinically stable, with no overt signs of heart failure, device malfunction, or systemic illness. Laboratory abnormalities were present but mild, lacking the dramatic elevations in plasma free hemoglobin and lactate dehydrogenase that classically accompany pump thrombosis and that form the backbone of established diagnostic algorithms. What stood out instead was the device’s own telemetry: an abrupt decline in estimated pump flow recorded by the system monitor. In a device that continuously reports flow, power, pulsatility index, and speed, a sudden fall in flow is a mechanical statement that something is obstructing the blood’s path through the pump or its conduits.

The clinical team pursued the signal aggressively. Contrast-enhanced computed tomography was performed, and the imaging raised suspicion of thrombus formation within the outflow graft, the conduit that carries blood from the pump into the aorta. Faced with a plausible mechanical obstruction and a device already showing declining performance, the surgeons proceeded to an emergent pump exchange. The decision proved prescient. Subsequent analysis of the explanted device by the manufacturer demonstrated thrombus attached to the metallic edge at the inflow aspect of the pump, the region where blood enters from the left ventricle. Notably, no thrombus was identified on the rotor or on the impeller blade surfaces, indicating that the clot had lodged at the pump’s entry rather than accumulating on its moving parts.

This anatomical detail matters because it helps explain the paradoxical laboratory picture. Hemolysis, the destruction of red blood cells that releases free hemoglobin into plasma, is most severe when thrombus interacts directly with the rapidly spinning rotor. A thrombus sitting at the inflow edge, partially obstructing inflow rather than churning against the impeller, can reduce flow while generating comparatively little shear-related blood damage. The result is a thrombotic event that evades the standard biochemical radar. The authors argue that this case exposes the limitations of relying solely on laboratory findings for early detection and prediction of early HeartMate 3 pump thrombosis, and they emphasize that an abrupt decline in pump flow, even in the absence of marked hemolysis or increased pump power, may represent an early and clinically important warning indicator.

The diagnostic challenge in continuous-flow ventricular assist devices is well documented in the literature the authors cite. Algorithms developed more than a decade ago, including the widely used approach published by Goldstein and colleagues in 2013, built diagnosis around a constellation of findings: hemolysis, rising pump power, low flow, and echocardiographic abnormalities. Later work by Scandroglio and colleagues refined the evaluation of blood flow obstructions, and a systematic analysis by Kaufmann and colleagues in 2022 catalogued thrombus formation at the inflow cannula of continuous-flow devices. Yet the HeartMate 3’s hemocompatibility profile has shifted the epidemiology. Pump thrombosis is now so uncommon that individual cases carry outsized educational value, and each one refines the community’s understanding of how the complication can present.

Early postoperative thrombosis is a particularly treacherous subset. Reported cases include thrombosis within one hour of implantation, intraoperative pump thrombosis, and acute events in the first days after surgery, as documented by Shah and colleagues, Karuppiah and colleagues, and Bunge and colleagues in separate reports. The early period is a perfect storm of prothrombotic conditions: fresh surgical surfaces, inflammatory activation, altered anticoagulation management, and a healing heart adapting to unloading by the new device. A patient in this window who develops a flow abnormality may be dismissed as having volume shifts, arrhythmia, or right heart dysfunction, all of which can alter pump flow estimates. The Kurume case demonstrates why an abrupt change should instead prompt immediate structural evaluation rather than watchful waiting.

The technology itself deserves attention in understanding why flow telemetry is such a sensitive indicator. The HeartMate 3 operates at a fixed speed set by the clinician, typically around 5,000 to 6,000 revolutions per minute, and the controller estimates flow from the relationship between power consumption and speed. When inflow becomes obstructed, the pump essentially runs against a partial vacuum, and the estimated flow falls even though the impeller continues spinning at its commanded speed. Pump power, by contrast, may change little when the obstruction is at the inflow rather than within the rotor region, which is precisely the pattern observed here. The artificial pulse, a periodic speed modulation unique to the HeartMate 3 that washes all surfaces of the pump, also influences the flow waveform, and clinicians familiar with its normal pulsatility signature can detect deviations that suggest inflow problems. In this case, the flow decline was abrupt enough to stand out against the patient’s baseline, functioning as the device’s own distress signal.

Contrast-enhanced computed tomography emerged as the decisive diagnostic step, and its role in this case reinforces a growing consensus that imaging should be part of the early evaluation of suspected device obstruction. Echocardiography remains the first-line tool for assessing inflow cannula position, ventricular size, and valve function, but it can miss thrombus within the outflow graft or at the pump’s inflow edge. Computed tomography with contrast offers a direct view of the entire blood path from ventricle to aorta, and in this patient it converted an ambiguous telemetry finding into a surgical indication. The authors’ sequence, from flow alarm to laboratory review to cross-sectional imaging to emergent exchange, effectively models the pathway they believe should be followed when abrupt flow decline appears without an obvious hemodynamic explanation.

The broader message for the mechanical circulatory support community is one of vigilance and humility about traditional markers. The HeartMate 3 has transformed outcomes for patients with advanced heart failure, with five-year results from the MOMENTUM 3 trial showing superior survival and fewer adverse events than earlier devices. But hemocompatibility is not immunity, and the rare thrombosis that does occur may present in atypical ways. The Kurume team, supported in part by a Japan Society for the Promotion of Science KAKENHI grant, closes their report with a clear clinical directive: prompt recognition and intervention are essential to prevent clinical deterioration. For the thousands of clinicians who monitor HeartMate 3 patients through daily device downloads, the case reframes a familiar number on the screen. An abrupt fall in pump flow is not a curiosity to be observed; it is a call to action, potentially the first and only warning that a life-sustaining pump is beginning to clot from the inside.

Subject of Research: Early detection of HeartMate 3 pump thrombosis using abrupt pump flow decline as an initial warning indicator

Article Title: Abrupt flow decline as the initial indicator of early HeartMate 3 pump thrombosis

Article References: Ishii, Y., Kato, T. S., Takagi, K., Sano, S., Yoshimatsu, S., Shinoda, M., Yanai, T., Shibata, T., Uehara, M., Uchimura, H., Sugihara, G., Fukumoto, Y., & Tayama, E. (2026). Abrupt flow decline as the initial indicator of early HeartMate 3 pump thrombosis. Journal of Artificial Organs, 29(4), Article 61. https://doi.org/10.1007/s10047-026-01588-1

Image Credits: AI Generated

DOI: 10.1007/s10047-026-01588-1

Keywords: HeartMate 3, pump thrombosis, LVAD, mechanical circulatory support, pump flow, hemolysis, outflow graft, computed tomography, heart failure, ventricular assist device, low flow alarm, device thrombosis

The HeartMate 3, a fully magnetically levitated continuous-flow pump, has become a workhorse of advanced heart failure therapy worldwide, offering durable support both as a bridge to transplantation and as destination therapy. Because the pump maintains a constant flow through the circulatory system, its external controller continuously estimates flow and triggers alarms when values fall below a preset low flow limit, or LFL. That alarm serves as an early warning for potentially dangerous conditions such as pump thrombosis, inflow obstruction, hypovolemia, or arrhythmias. The factory-standard setting is 2.5 liters per minute, but clinicians have increasingly recognized that some patients—particularly those of smaller body habitus—may run baseline flows close enough to that threshold that nuisance alarms become a daily occurrence, eroding quality of life and prompting careful discussions about whether the alarm limit can safely be lowered.

In a retrospective observational study published in the Journal of Artificial Organs, a team led by Hiroshi Nishioka of the National Cerebral and Cardiovascular Center in Suita, Osaka, and Takuma Sato of the same institution’s Department of Transplant Medicine set out to determine which preoperative characteristics predicted the need for postoperative replacement of the standard controller with one configured to a low flow limit of 2.0 liters per minute. The researchers analyzed 127 patients who underwent primary HeartMate 3 implantation at their center between June 2019 and March 2025. Of these, 78 patients maintained the standard 2.5 liter-per-minute controller throughout follow-up, while 49 required replacement with a controller set to the lower 2.0 liter-per-minute threshold.

The comparison between the two groups revealed a striking pattern. Patients who ultimately needed the lower alarm limit were significantly smaller across every anthropometric measure examined: they were shorter, weighed less, had lower body mass index, and, most consequentially, had smaller body surface area. They also tended to have a shorter history of heart failure before implantation. By contrast, the study found no significant differences between the groups in a broad battery of clinical, echocardiographic, and hemodynamic variables, suggesting that the conventional parameters clinicians often scrutinize before implantation—measures of cardiac function and pumping performance—did not separate the two groups.

To move from association to prediction, the researchers applied multivariate logistic regression, a statistical technique that evaluates each candidate variable’s independent contribution while holding the others constant. When all the clinical, laboratory, echocardiographic, and hemodynamic measurements were weighed together, body surface area emerged as the sole independent predictor of postoperative controller replacement. The effect size was dramatic: each unit increase in body surface area was associated with an odds ratio of 0.03, meaning that larger patients were overwhelmingly less likely to require the lower alarm limit. The 95 percent confidence interval ranged from 0.00 to 0.60, and the result reached statistical significance with a p-value of 0.022.

The team then used receiver operating characteristic curve analysis to translate that statistical association into a clinically usable threshold. This method plots a test’s sensitivity against its specificity across all possible cutoff values, allowing researchers to identify the value that best discriminates between groups. A preoperative body surface area of 1.43 square meters proved to be the optimal cutoff, yielding an area under the curve of 0.74—indicating moderate discriminatory power—with a specificity of 89.7 percent and a sensitivity of 38.8 percent. In practical terms, a patient whose body surface area falls below 1.43 square meters is very likely to be among those who will need the lower alarm limit, while the relatively modest sensitivity means that some patients above the cutoff will still require it. The authors are transparent about this trade-off: the threshold is highly specific but only moderately sensitive, making it best suited for identifying patients who clearly warrant a 2.0 liter-per-minute controller from the outset.

The clinical logic behind lowering the alarm limit in smaller patients rests on the physiology of continuous-flow circulatory support. Pump flow scales with the metabolic demands of the body, and smaller patients simply generate lower absolute flows at any given support setting. When baseline flows hover near 2.5 liters per minute, the standard alarm threshold produces frequent false alarms during routine activity, dehydration, or minor hemodynamic shifts. Frequent alarms are not merely an annoyance; studies of left ventricular assist device patients have linked alarm burden to anxiety, sleep disruption, and reduced quality of life, and they can lead patients and caregivers to become desensitized to alerts, potentially delaying recognition of genuine emergencies. Lowering the limit to 2.0 liters per minute preserves the protective function of the alarm for truly dangerous low-flow states while eliminating the constant noise of alerts triggered by the patient’s normal operating range.

Until now, however, the decision to swap the standard controller for a 2.0 liter-per-minute version has typically been reactive: clinicians implant the device with factory settings, observe alarm behavior over weeks or months, and then arrange for controller replacement in those who struggle. Each replacement carries practical costs—additional hospital visits, device reprogramming, patient education, and the logistics of exchanging a life-sustaining external component. The study’s authors argue that a proactive approach, guided by the 1.43 square meter body surface area threshold, could spare many smaller patients an unnecessary second procedure while ensuring that the alarm system remains calibrated to their physiology from day one. Because the cutoff is derived from a measurement taken routinely at every preoperative evaluation, implementing it would require no additional testing, only a change in configuration practice.

The findings come amid rapid growth in mechanical circulatory support. The most recent annual report from the Society of Thoracic Surgeons Interagency Registry for Mechanically Assisted Circulatory Support documented expanding use of the HeartMate 3 across age groups, including growing experience in pediatric and small-statured patients through networks such as the Advanced Cardiac Therapies Improving Outcomes Network. As the device is implanted in increasingly diverse populations, individualizing device settings becomes more pressing. The Japanese cohort studied here reflects a national experience in which body size distributions differ from those in Western registries, and the authors caution that their results derive from a single center; validation in larger, multi-center and ethnically diverse cohorts will be needed before the 1.43 square meter threshold can be adopted as a universal standard.

Nevertheless, the elegance of the result lies in its simplicity. In an era when artificial hearts are guided by sophisticated algorithms and magnetically levitated rotors, one of the most useful predictors of device configuration turns out to be a number calculated from height and weight. For clinicians implanting the HeartMate 3, the message is concrete: check the body surface area before surgery, and for patients below roughly 1.43 square meters, consider reaching for the 2.0 liter-per-minute controller at the start. For the growing community of patients living with these pumps, it could mean fewer alarms, fewer controller exchanges, and a device experience better matched to the bodies it sustains.

Subject of Research: Preoperative prediction of low flow limit controller configuration after HeartMate 3 implantation

Article Title: Preoperative predictors of low flow limit controller configuration following HeartMate 3 implantation

Article References: Nishioka, H., Sato, T., Komiyama, M., Iwanaga, K., Tonai, K., Kitahata, N., Takahashi, Y., Miyagawa, S., Sawada, K., Yotsuida, H., Tadokoro, N., Fukushima, S., Fujita, T., Fujisato, T., & Tsukamoto, Y. (2026). Preoperative predictors of low flow limit controller configuration following HeartMate 3 implantation. Journal of Artificial Organs, 29(4), Article 62. https://doi.org/10.1007/s10047-026-01590-7

Image Credits: AI Generated

DOI: 10.1007/s10047-026-01590-7

Keywords: HeartMate 3, left ventricular assist device, body surface area, low flow limit, low-flow alarm, controller configuration, advanced heart failure, mechanical circulatory support, quality of life, cardiac surgery, LVAD, predictive threshold